
Please try another search
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Mountain View, California.
Name | Age | Since | Title |
---|---|---|---|
Ramtin Agah | 59 | 2009 | Founder, Chairman of Board & Chief Medical Officer |
Shaun R. Bagai | 48 | 2014 | CEO, Secretary & Director |
Una S. Ryan | 83 | 2013 | Independent Director |
Michael Pishvaian | - | 2017 | Member of Advisory Board |
Lawrence J. Marton | 81 | 2012 | Independent Director |
Karyn A. Goodman | - | 2017 | Member of Advisory Board |
Kirsten Angela Macfarlane | 61 | 2018 | Independent Director |
Margaret A. Tempero | - | 2023 | Member of Scientific Advisory Board |
Robert Jay Spiegel | 76 | 2023 | Independent Director |
Michel Ducreux | - | 2023 | Member of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review